YITU Attended ICCV 2019 with Self-developed Cloud AI Chip, Showcasing Integrated Software and Hardware Strength
1.11.2019 13:00:00 EET | Business Wire | Press release
The 17th International Conference on Computer Vision (ICCV 2019) was convened in Seoul, South Korea this week. YITU Technology attended the conference with its latest researches. Known as the world’s top-notch computer vision conference, ICCV is held once every two years, of which the papers and topics manifest the highest research level and technical growth trend in the field of computer vision.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191101005240/en/
YITU AI chip QuestCore TM (Photo: Business Wire)
As a globally leading artificial intelligence company, YITU has been always standing at the frontier of AI innovations. From October 29th to November 1st, AI researchers from YITU present their up-to-date research findings and industrial practices at the ICCV 2019, including QuestCoreTM, a cloud AI chip developed by YITU, so as to communicate with and learn from a wider range of research communities.
“The peak of artificial intelligence algorithm performance has shifted from academia to industry,” said Dr. Yan Shuicheng, CTO of YITU, “Academia and industry need in-depth cooperation, to better boost increasing peak performance of the entire AI ecological algorithm.”
As a world-known scholar in computer vision and machine learning, Dr. Yan joined YITU in August this year, the company's strong R&D and engineering strength is one of the important reasons for him to join. Dr. Yan, as an IEEE Fellow, IAPR Fellow and ACM Distinguished Scientist, has published more than 600 papers in top international journals and conferences, with more than 40,000 citations, H-index 98.
YITU released its self-developed cloud AI chip QuestCoreTM in May, 2019. Integrated with its world-class AI algorithm and advanced chip design philosophy, it is so far the most intelligent and cost-effective video analysis chip in the world. This chip indicates a successful practice of YITU to follow the strong coupling trend between AI algorithms and chip design. Relevant achievements are also exhibited on ICCV 2019.
According to data from Tsinghua University, computer vision applications accounted for nearly 35% of the total artificial intelligence applications in 2019, and have become an important support for the development of various industries.
YITU is building the Visual Computing National New Generation Artificial Intelligence Open Innovation Platforman, a national AI infrastructure, to align with the developers of algorithm, chip and product, and provide full chain optimization services covering algorithm, chip and entire tool chain.
“We will help to enhance the overall performance of visual computing smart industry solution,” said Dr. Yan Shuicheng. “Help to integrate development experience and domain knowledge, and promote industrial innovation and cooperation."
About YITU
YITU Technology is one of the few startups in the world that has pioneered many cutting-edge technologies in many critical Artificial Intelligent (AI) fields such as computer vision, speech recognition, natural language processing, intelligent decision-making and AI chips.
YITU Technology is dedicated to advancing breakthrough technologies in AI. Powered by world-class AI algorithms, YITU's self-developed AI chip QuestCore™ can be applied to a variety of scenarios to provide cost-effective and market-competitive solutions. YITU is the only company worldwide to be awarded championship in facial recognition vendor test three times by National Institute of Standards and Technology (NIST), as well as first place in the test hosted by the Intelligence Advanced Research Projects Activity (IARPA). YITU’s self-developed speech recognition technology has been tested to be best-in-class for the Mandarin language. Nature Medicine, a leading academic journal, published on YITU’s latest breakthrough in intelligent pediatric diagnostic technology based on NLP this February, which has been so far the highest-level paper in the field of artificial intelligence research in China.
Leveraging AI technology, YITU is empowering diverse industries. It provides world-leading innovative technologies and products in several sectors including Intelligent City, Smart Finance, Intelligent Healthcare, Smart Retail, AI Chips and AI Pharmaceuticals. YITU is so far the only AI company nationwide able to provide intelligent management technology in mega-cities and complex conditions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191101005240/en/
Contact information
Yitu Tech
Contact name: Alice Deng
Tel:021 - 52559588
Email:media@yitu-inc.com
Website: https://www.yitutech.com/en
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom